Udayavni Special

Israeli scientist granted US patent for COVID-19 vaccine design

PTI, Apr 20, 2020, 7:46 AM IST

Tel Aviv: In a major breakthrough, an Israeli scientist at Tel Aviv University has been granted a US patent for his innovative vaccine design for the corona family of viruses, a press statement by the varsity said on Sunday, April 19.

The patent has been granted by the United States Patent and Trademark Office (USPTO).

The vaccine is proposed by Professor Jonathan Gershoni of the School of Molecular Cell Biology and Biotechnology at the university’s George S. Wise Faculty of Life Sciences.

It targets the novel coronavirus’ Achilles’ heel, its Receptor Binding Motif (RBM), the most vulnerable point in a Coronavirus’ structure, a critical form that enables the virus to bind to and infect a target cell.

“The development of the vaccine could still take several months before it goes for clinical trials,” it said.

“The vaccine would reconstruct the coronavirus’ RBM, a tiny feature of its spike protein. Though the virus uses many different proteins to replicate and invade cells, the spike protein is the major surface protein that it uses to bind to a receptor another protein that acts as a doorway into a human cell.

“After the spike protein binds to the human cell receptor, the viral membrane fuses with the human cell membrane, allowing the genome of the virus to enter human cells and begin infection,” Gershoni said in the statement.

Gershoni has been working on the coronaviruses for the last 15 years, developing a method of reconstructing and reconstituting the RBM feature of the spike protein in SARS CoV and subsequently in MERS CoV.

The moment the genome of the new virus was published in early January 2020, we began the process of reconstituting the RBM of SARS CoV2, the virus that causes COVID-19, and expects to have a reconstituted RBM of the new virus soon,” he said.

“This will be the basis for a new vaccine, which could be ready for use within a year to a year-and-a-half, he said.

Gershoni said that the discovery and production of a functional RBM for the new coronavirus is fundamental and critical for the production of the vaccine they propose.

The novel coronavirus, that originated in China, has wreaked havoc across the globe by infecting 2.3 million people and causing over 160,000 deaths.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

IMA scam: Former Congress minister Roshan Baig secures bail

US court orders full reinstatement of DACA to protect undocumented immigrants, including Indians

India biggest buyer of COVID-19 vaccine with 1.6 bn doses, experts say this could cover 60 pc population

Union ministers assemble at PM Modi’s residence ahead of talks with farmers

Bahrain becomes second country to approve Pfizer-BioNTech vaccine

25-Year-Old Jeweller’s 12,638-Diamond Ring Sets World Record

“Band Baaja Baraat” Gang attended weddings for theft, used minors: Cops

Related Articles More

‘How airflow inside car may affect COVID-19 transmission risk decoded’

India biggest buyer of COVID-19 vaccine with 1.6 bn doses, experts say this could cover 60 pc population

Haryana Health Minister Anil Vij tests positive for COVID-19

COVID-19 vaccine will not be mandatory: Biden

K’taka COVID-19 update: 1247 new cases, 877 discharges, 13 dead on Dec 3


Karnataka bandh over Maratha board | Udayavani

M’luru boat tragedy: Search operation still on for Ansar’s body

Deer falls into well, rescued

Without sulking from his illness, this young man changed his life through agriculture

State government must immediately bring in anti-cow slaughter law: Sri Vishwa Prasanna Tirtha Swamiji

Latest Additions

Singapore becomes first country to approve lab-grown meat: All you need to know

Super 30 founder to be expert at KBC

Petrol Price at Breach Rs 83 Per Litre Mark After Two Years, Diesel at 73.32

Huge validation to headline movies: Bhumi Pednekar on ‘Durgamati’

‘Belgavi is ours, anyone who has lived in K’taka for 10 years is Kannadiga’

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.